Nivolumab Plus Relatlimab: First Approval

被引：0
作者：
Julia Paik
机构：
[1] Springer Nature,
来源：
Drugs | 2022年 / 82卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag™) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers. Both drugs are immunoglobulin G4 (IgG4) monoclonal antibodies developed to target immune checkpoints, with nivolumab targeting the programmed cell death protein 1 (PD-1) receptor and relatlimab being a newly developed, first-in-class drug targeting the lymphocyte-activation gene 3 (LAG-3) protein. In March 2022, nivolumab plus relatlimab received its first approval in the USA for the treatment of unresectable or metastatic melanoma in adult patients and paediatric patients aged ≥ 12 years who weigh ≥ 40 kg. This article summarizes the milestones in the development of this combination therapy leading to this first approval for unresectable or metastatic melanoma.
引用
收藏
页码：925 / 931
页数：6
相关论文
共 27 条
  • [1] Shi AP(2022)Immune checkpoint LAG3 and its ligand FGL1 in cancer Front Immunol 12 1-11
  • [2] Tang XY(2018)Inhibitors of the PD-1 pathway in tumor therapy J Immunol 200 375-383
  • [3] Xiong YL(2020)Immunotherapies and combination strategies for immuno-oncology Int J Mol Sci 21 5009-1086
  • [4] LaFleur MW(2018)Fundamental mechanisms of immune checkpoint blockade therapy Cancer Discov 8 1069-34
  • [5] Muroyama Y(2021)LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia Cancers (Basel). 13 2122-v612
  • [6] Drake CG(2022)Model-informed clinical pharmacology (CP) profile of a novel fixed-dose combination (FDC) of relatlimab and nivolumab in patients with solid tumors Clin Pharmacol Ther 111 S61-undefined
  • [7] Barbari C(2022)Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma N Engl J Med 386 24-undefined
  • [8] Fontaine T(2022)Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: overall survival and response rates from RELATIVITY-047 (CA224-047) J Clin Oncol 40 v611-undefined
  • [9] Parajuli P(2017)Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarkerenriched populations Ann Oncol 28 undefined-undefined
  • [10] Wei SC(undefined)undefined undefined undefined undefined-undefined
123